Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

PubWeight™: 9.68‹?› | Rank: Top 0.1%

🔗 View Article (PMID 8558223)

Published in J Clin Oncol on January 01, 1996

Authors

J M Kirkwood1, M H Strawderman, M S Ernstoff, T J Smith, E C Borden, R H Blum

Author Affiliations

1: Division of Medical Oncology, University of Pittsburgh, PA 15213-2582, USA.

Articles citing this

(truncated to the top 100)

The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov (2009) 6.23

Genomic Classification of Cutaneous Melanoma. Cell (2015) 3.91

Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist (2011) 2.89

Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg (1996) 2.68

Immunotherapy of cancer in 2012. CA Cancer J Clin (2012) 2.12

Missing data in clinical studies: issues and methods. J Clin Oncol (2012) 2.05

Immune regulation of cancer. J Clin Oncol (2010) 1.99

Toxicity and feasibility of adjuvant high-dose interferon alpha-2b in patients with melanoma in clinical oncologic practice. Br J Cancer (1999) 1.96

Recent advances in the care of the patient with malignant melanoma. Ann Surg (1997) 1.92

Transient T cell depletion causes regression of melanoma metastases. J Transl Med (2008) 1.61

Current management and novel agents for malignant melanoma. J Hematol Oncol (2012) 1.53

Toxicities of Immunotherapy for the Practitioner. J Clin Oncol (2015) 1.50

Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer. Nat Commun (2011) 1.49

The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol (2013) 1.46

The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma. Br J Cancer (2000) 1.45

Impact of BRAF mutation status in the prognosis of cutaneous melanoma: an area of ongoing research. Ann Transl Med (2015) 1.42

VARIABLE SELECTION FOR REGRESSION MODELS WITH MISSING DATA. Stat Sin (2010) 1.40

Sentinel lymph node biopsy in the management of patients with primary cutaneous melanoma: review of a large single-institutional experience with an emphasis on recurrence. Ann Surg (2001) 1.36

Analysis of the genome to personalize therapy for melanoma. Oncogene (2010) 1.33

Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases. BMC Cancer (2011) 1.28

Adjuvant therapy of melanoma with interferon: lessons of the past decade. J Transl Med (2008) 1.28

Cytokines in cancer immunotherapy. Cancers (Basel) (2011) 1.26

Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma. J Clin Oncol (2011) 1.24

Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma. Mol Ther (2008) 1.22

Flexible Cure Rate Modeling Under Latent Activation Schemes. J Am Stat Assoc (2007) 1.20

Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694. J Clin Oncol (2008) 1.19

Long-term survival in 2,505 patients with melanoma with regional lymph node metastasis. Ann Surg (2002) 1.15

The Role of B-RAF Mutations in Melanoma and the Induction of EMT via Dysregulation of the NF-κB/Snail/RKIP/PTEN Circuit. Genes Cancer (2010) 1.14

Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-α or TLR-9 agonist and GM-CSF with peptide vaccination. J Immunother (2012) 1.13

IFN-α in the treatment of melanoma. J Immunol (2012) 1.12

Role of interferon {alpha} (IFN{alpha})-inducible Schlafen-5 in regulation of anchorage-independent growth and invasion of malignant melanoma cells. J Biol Chem (2010) 1.12

Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer. J Leukoc Biol (2004) 1.12

STAT signaling in the pathogenesis and treatment of cancer. Mol Med (1999) 1.11

The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: where we have been, are, and will be. Clin Cancer Res (2013) 1.10

Translating tumor antigens into cancer vaccines. Clin Vaccine Immunol (2010) 1.09

Nivolumab in melanoma: latest evidence and clinical potential. Ther Adv Med Oncol (2015) 1.09

Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. J Clin Oncol (2014) 1.07

Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway. Pharmgenomics Pers Med (2014) 1.06

A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire. Mol Med (1998) 1.04

Interferon lambda: a new sword in cancer immunotherapy. Clin Dev Immunol (2011) 1.04

Tumour-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon alpha treatment. Br J Cancer (1996) 1.03

Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomes. Int J Radiat Oncol Biol Phys (2014) 1.03

Correlation of molecular human leukocyte antigen typing and outcome in high-risk melanoma patients receiving adjuvant interferon. Cancer (2010) 1.02

Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG). Br J Cancer (2001) 1.02

U.S. Food and Drug Administration Approval: peginterferon-alfa-2b for the adjuvant treatment of patients with melanoma. Oncologist (2012) 1.01

Adjuvant therapy for melanoma. Cancer J (2012) 1.01

A gene therapy for cancer using intramuscular injection of plasmid DNA encoding interferon alpha. Proc Natl Acad Sci U S A (1999) 1.01

A multimarker prognostic assay for primary cutaneous melanoma. Clin Cancer Res (2009) 1.01

Statistical issues and challenges in immuno-oncology. J Immunother Cancer (2013) 0.99

Reduced level of CD44 and hyaluronan associated with unfavorable prognosis in clinical stage I cutaneous melanoma. Am J Pathol (2000) 0.98

Immune checkpoint inhibitors in clinical trials. Chin J Cancer (2014) 0.98

Cancer immunotherapy in clinical practice -- the past, present, and future. Chin J Cancer (2014) 0.98

Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade. J Clin Invest (2015) 0.98

Noncutaneous malignant melanoma: a prognostic model from a retrospective multicenter study. BMC Cancer (2010) 0.97

Systemic interferon-alpha (IFN-alpha) treatment leads to Stat3 inactivation in melanoma precursor lesions. Mol Med (1999) 0.97

Associations of 9p21 variants with cutaneous malignant melanoma, nevi, and pigmentation phenotypes in melanoma-prone families with and without CDKN2A mutations. Fam Cancer (2010) 0.97

Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma. Br J Cancer (1998) 0.94

Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study. Br J Cancer (2001) 0.93

Next generation oncology drug development: opportunities and challenges. Nat Rev Clin Oncol (2009) 0.93

Latest advances in the care of the patient with melanoma. Ann Surg (1998) 0.93

Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment. J Transl Med (2010) 0.93

Clinical and immunologic basis of interferon therapy in melanoma. Ann N Y Acad Sci (2009) 0.92

smcure: an R-package for estimating semiparametric mixture cure models. Comput Methods Programs Biomed (2012) 0.92

Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma. BMC Cancer (2011) 0.91

Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma. Cancer Chemother Pharmacol (2010) 0.91

Melanoma induces immunosuppression by up-regulating FOXP3(+) regulatory T cells. J Surg Res (2007) 0.91

Stable synthetic bacteriochlorins overcome the resistance of melanoma to photodynamic therapy. FASEB J (2010) 0.91

Modelling population-based cancer survival trends using join point models for grouped survival data. J R Stat Soc Ser A Stat Soc (2009) 0.91

Prognostic significance of autoimmunity during treatment of melanoma with interferon. Semin Immunopathol (2011) 0.90

Suppression of angiogenesis and therapy of human colon cancer liver metastasis by systemic administration of interferon-alpha. Neoplasia (2001) 0.90

Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV). The new American Joint Committee on Cancer. Br J Cancer (2002) 0.90

Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12. Semin Oncol (2015) 0.89

Final Results of the Sunbelt Melanoma Trial: A Multi-Institutional Prospective Randomized Phase III Study Evaluating the Role of Adjuvant High-Dose Interferon Alfa-2b and Completion Lymph Node Dissection for Patients Staged by Sentinel Lymph Node Biopsy. J Clin Oncol (2016) 0.89

Melanoma in pediatric, adolescent, and young adult patients. Semin Oncol (2009) 0.89

Clinical relevance of molecular staging for melanoma: comparison of RT-PCR and immunohistochemistry staining in sentinel lymph nodes of patients with melanoma. Ann Surg (2000) 0.89

Modulation of SOCS protein expression influences the interferon responsiveness of human melanoma cells. BMC Cancer (2010) 0.88

Effective melanoma immunotherapy in mice by the skin-depigmenting agent monobenzone and the adjuvants imiquimod and CpG. PLoS One (2010) 0.88

Future of radiation therapy for malignant melanoma in an era of newer, more effective biological agents. Onco Targets Ther (2011) 0.88

Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types. Onco Targets Ther (2015) 0.88

Challenges in the development of an autologous heat shock protein based anti-tumor vaccine. Hum Vaccin Immunother (2012) 0.88

Regression of advanced melanoma upon withdrawal of immunosuppression: case series and literature review. Med Oncol (2009) 0.88

Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011". J Transl Med (2012) 0.87

Recent developments in plastic surgery. BMJ (2002) 0.87

Targeting nodal in conjunction with dacarbazine induces synergistic anticancer effects in metastatic melanoma. Mol Cancer Res (2015) 0.86

Pump-probe imaging of pigmented cutaneous melanoma primary lesions gives insight into metastatic potential. Biomed Opt Express (2015) 0.86

Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial. J Transl Med (2010) 0.85

Sinonasal mucosal melanoma: a 13-year experience at a single institution. Skull Base (2009) 0.85

Understanding the biology of melanoma and therapeutic implications. Hematol Oncol Clin North Am (2014) 0.85

The past, present and future of immunotherapy against tumor. Transl Lung Cancer Res (2015) 0.85

Value of sentinel node status as a prognostic factor in melanoma: prospective observational study. BMJ (2006) 0.84

Health management program: factors influencing completion of therapy with high-dose interferon alfa-2b for high-risk melanoma. Curr Oncol (2008) 0.84

A phase I trial of bortezomib and interferon-α-2b in metastatic melanoma. J Immunother (2014) 0.84

Epigenetic regulation of the TRAIL/Apo2L apoptotic pathway by histone deacetylase inhibitors: an attractive approach to bypass melanoma immunotherapy resistance. Am J Clin Exp Immunol (2013) 0.84

Interferon-alpha (IFN-alpha) stimulates anti-melanoma cytotoxic T lymphocyte (CTL) generation in mixed lymphocyte tumour cultures (MLTC). Clin Exp Immunol (2000) 0.84

Biochemotherapy of metastatic malignant melanoma. Predictive value of tumour-infiltrating lymphocytes. Br J Cancer (2001) 0.84

Biological factors, tumor growth kinetics, and survival after metastasectomy for pulmonary melanoma. Ann Surg Oncol (2009) 0.84

Trends in the treatment and survival for local and regional cutaneous melanoma in a US population-based study. Melanoma Res (2011) 0.83

Immunotherapy for solid tumors--a review for surgeons. J Surg Res (2013) 0.83

Outcomes for lymph node-positive cutaneous melanoma over two decades. World J Surg (2011) 0.83

Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2a. Br J Cancer (1998) 0.83

Articles by these authors

Pain and its treatment in outpatients with metastatic cancer. N Engl J Med (1994) 9.54

Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol (1999) 5.95

High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol (2001) 4.84

Genetic diversity among Botulinum Neurotoxin-producing clostridial strains. J Bacteriol (2006) 4.75

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol (2000) 4.60

The site of attachment in human rhinovirus 14 for antiviral agents that inhibit uncoating. Science (1986) 4.40

Hospital and physician volume or specialization and outcomes in cancer treatment: importance in quality of cancer care. J Clin Oncol (2000) 4.01

The three-dimensional structure of canine parvovirus and its functional implications. Science (1991) 3.87

Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis (2003) 3.73

Nucleocapsid and glycoprotein organization in an enveloped virus. Cell (1995) 3.66

2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol (2000) 3.38

Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci U S A (2002) 3.16

Telling the truth about terminal cancer. JAMA (1998) 3.07

Adriamycin. A new anticancer drug with significant clinical activity. Ann Intern Med (1974) 2.77

Antiviral agent blocks breathing of the common cold virus. Proc Natl Acad Sci U S A (1998) 2.71

Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg (1996) 2.68

A clinical review of bleomycin--a new antineoplastic agent. Cancer (1973) 2.53

Crystal structure of human rhinovirus serotype 1A (HRV1A). J Mol Biol (1989) 2.49

Fibroblasts as sentinel cells. Synthesis of chemokines and regulation of inflammation. Am J Pathol (1997) 2.47

Association of heart rate variability with occupational and environmental exposure to particulate air pollution. Circulation (2001) 2.46

Rabbit macrophage interferons. I. Conditions for biosynthesis by virus-infected and uninfected cells. J Exp Med (1967) 2.46

Immunoregulatory properties of ISG15, an interferon-induced cytokine. Proc Natl Acad Sci U S A (1996) 2.45

Factors influencing cosmetic outcome and complication risk after conservative surgery and radiotherapy for early-stage breast carcinoma. J Clin Oncol (1992) 2.42

Control of cytomegalovirus retinitis using sustained release of intraocular ganciclovir. Arch Ophthalmol (1993) 2.39

A retrospective cohort study of lung cancer and diesel exhaust exposure in railroad workers. Am Rev Respir Dis (1988) 2.38

Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J Clin Oncol (2000) 2.37

Structural analysis of a series of antiviral agents complexed with human rhinovirus 14. Proc Natl Acad Sci U S A (1988) 2.30

Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol (1993) 2.28

Recent skin self-examination and doctor visits in relation to melanoma risk and tumour depth. Br J Dermatol (2012) 2.20

Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ (2004) 2.17

Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg (1993) 2.08

Effective strategy for prenatal prediction of Duchenne and Becker muscular dystrophy. Lancet (1987) 2.08

A case-control study of lung cancer and diesel exhaust exposure in railroad workers. Am Rev Respir Dis (1987) 2.07

Human polyomavirus infections with JC virus and BK virus in renal transplant patients. Ann Intern Med (1980) 2.07

Tissue-shrinkage correction factor in the calculation of prostate cancer volume. Am J Surg Pathol (1996) 2.06

Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res (1998) 2.04

Encephalopathy and fatty degeneratiof on the viscera in northeastern Thailand. Clinical syndrome and epidemiology. Pediatrics (1971) 2.00

In vitro and in vivo secretion of human ISG15, an IFN-induced immunomodulatory cytokine. J Immunol (1996) 1.98

The role of autolysins during vegetative growth of Bacillus subtilis 168. Microbiology (1998) 1.97

Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol (1998) 1.94

Genetic and molecular analyses of spontaneous mutants of human rhinovirus 14 that are resistant to an antiviral compound. J Virol (1989) 1.92

Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res (1987) 1.87

Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Res (2000) 1.86

Neutralizing human monoclonal antibodies binding multiple serotypes of botulinum neurotoxin. Protein Eng Des Sel (2010) 1.80

Physicochemical and morphological relationships of some arthropod-borne viruses to bluetongue virus--a new taxonomic group. Physiocochemical and serological studies. J Gen Virol (1971) 1.78

Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer. Estimates using decision analysis while awaiting clinical trial results. JAMA (1992) 1.77

Physical and biological properties of dengue-2 virus and associated antigens. J Virol (1970) 1.75

Interferon-induced indoleamine 2,3-dioxygenase activity inhibits Chlamydia psittaci replication in human macrophages. J Interferon Res (1989) 1.74

Preferential induction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2: correlation with TRAIL/Apo2L induction in melanoma cell lines. Clin Cancer Res (2001) 1.73

Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol (2000) 1.71

Measuring standards of care for early breast cancer in an insured population. J Clin Oncol (1997) 1.71

Induction of tryptophan degradation in vitro and in vivo: a gamma-interferon-stimulated activity. J Interferon Res (1986) 1.70

Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model. N Engl J Med (1991) 1.67

Biologic-response-modifier-induced indoleamine 2,3-dioxygenase activity in human peripheral blood mononuclear cell cultures. J Immunol (1987) 1.65

Molecular evolution of antibody affinity for sensitive detection of botulinum neurotoxin type A. J Mol Biol (2005) 1.62

Pulmonary function in firefighters: acute changes in ventilatory capacity and their correlates. Br J Ind Med (1979) 1.61

Homozygous deletions within human chromosome band 9p21 in melanoma. Proc Natl Acad Sci U S A (1992) 1.58

Physicochemical and morphological relationships of some arthropod-borne viruses to bluetongue virus--a new taxonomic group. Electron microscopic studies. J Gen Virol (1971) 1.56

The cloning and sequence analysis of the aspC and tyrB genes from Escherichia coli K12. Comparison of the primary structures of the aspartate aminotransferase and aromatic aminotransferase of E. coli with those of the pig aspartate aminotransferase isoenzymes. Biochem J (1986) 1.55

The efficacy of specimen radiography in evaluating the surgical margins of impalpable breast carcinoma. AJR Am J Roentgenol (1994) 1.54

High-dose cisplatin and dacarbazine in the treatment of metastatic melanoma. J Natl Cancer Inst (1990) 1.51

Concepts of fever: recent advances and lingering dogma. Clin Infect Dis (1997) 1.50

Safety, accuracy, and diagnostic yield of needle localization biopsy of the breast performed using local anesthesia. J Am Coll Surg (1994) 1.49

Modeling particle exposure in U.S. trucking terminals. Environ Sci Technol (2006) 1.49

Dose coefficients for the embryo and foetus following intakes of radionuclides by the mother. J Radiol Prot (2002) 1.47

A human 15-kDa IFN-induced protein induces the secretion of IFN-gamma. J Immunol (1991) 1.47

A flow cytometric method to estimate the precursor frequencies of cells proliferating in response to specific antigens. J Immunol Methods (1999) 1.46

The optimal timing of autologous bone marrow transplantation in Hodgkin's disease patients after a chemotherapy relapse. J Clin Oncol (1992) 1.45

2000 update of American Society of Clinical Oncology colorectal cancer surveillance guidelines. J Clin Oncol (2000) 1.43

Hyperinsulinism/hyperammonemia syndrome in children with regulatory mutations in the inhibitory guanosine triphosphate-binding domain of glutamate dehydrogenase. J Clin Endocrinol Metab (2001) 1.42

Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol (1987) 1.42

Rapid detection and identification of JC virus and BK virus in human urine by using immunofluorescence microscopy. J Clin Microbiol (1980) 1.42

Estimating glomerular filtration rate in diabetes: a comparison of cystatin-C- and creatinine-based methods. Diabetologia (2006) 1.42

Interferon-induced indoleamine 2,3-dioxygenase activity in human mononuclear phagocytes. J Leukoc Biol (1989) 1.41

The use of viscoelastic substances in the drainage of postoperative suprachoroidal hemorrhage. Ophthalmic Surg (1989) 1.40

Deletions of fetal and adult muscle cDNA in Duchenne and Becker muscular dystrophy patients. EMBO J (1987) 1.40

Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate. Infect Immun (1998) 1.39

Health effects of gasoline exposure. II. Mortality patterns of distribution workers in the United States. Environ Health Perspect (1993) 1.39

Fungal virus capsids, cytoplasmic compartments for the replication of double-stranded RNA, formed as icosahedral shells of asymmetric Gag dimers. J Mol Biol (1994) 1.39

Recommended colorectal cancer surveillance guidelines by the American Society of Clinical Oncology. J Clin Oncol (1999) 1.39

Pulmonary effects of exposures in silicon carbide manufacturing. Br J Ind Med (1984) 1.39

Breast conservation therapy for early stage breast carcinoma with outstanding 10-year locoregional control rates: a case for aggressive therapy to the tumor bearing quadrant. Int J Radiat Oncol Biol Phys (1993) 1.38

Pathologic analysis of advanced adult soft tissue sarcomas, bone sarcomas, and mesotheliomas. The Eastern Cooperative Oncology Group (ECOG) experience. Cancer (1989) 1.38

Corneal traction suture in trabeculectomy. Ophthalmic Surg (1991) 1.37

Estimation of the diesel exhaust exposures of railroad workers: I. Current exposures. Am J Ind Med (1988) 1.35

Tumor biology of infiltrating lobular carcinoma. Implications for management. Ann Surg (1995) 1.35

Activation of human orbital fibroblasts through CD40 engagement results in a dramatic induction of hyaluronan synthesis and prostaglandin endoperoxide H synthase-2 expression. Insights into potential pathogenic mechanisms of thyroid-associated ophthalmopathy. J Biol Chem (1998) 1.34

The interferon refractory state: in vivo and in vitro studies of its mechanism. J Immunol (1971) 1.34

Human lung tryptase. Purification and characterization. J Biol Chem (1984) 1.33

Interferons and indoleamine 2,3-dioxygenase: role in antimicrobial and antitumor effects. Experientia (1989) 1.33

Human orbital fibroblasts are activated through CD40 to induce proinflammatory cytokine production. Am J Physiol (1998) 1.32

Clinical significance of histopathologic patterns of cardiac amyloidosis. Mayo Clin Proc (1984) 1.30

Targeted modification of the apolipoprotein B gene results in hypobetalipoproteinemia and developmental abnormalities in mice. Proc Natl Acad Sci U S A (1993) 1.28

Variation in staging and treatment of local and regional breast cancer in the elderly. Breast Cancer Res Treat (1996) 1.27

Factors that determine the treatment for local and regional prostate cancer. Med Care (1996) 1.27

Functional TSH receptor in human abdominal preadipocytes and orbital fibroblasts. Am J Physiol Cell Physiol (2000) 1.27

A prospective study of hepatic imaging in the detection of metastatic disease. Ann Surg (1982) 1.26

Conformational variability of a picornavirus capsid: pH-dependent structural changes of Mengo virus related to its host receptor attachment site and disassembly. Virology (1990) 1.26